Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.1.24NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.320NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.33NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.635NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.21NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.14NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AY.19 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
N.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AM.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.15 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.113NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GA.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.5.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CA.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BM.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.46NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CU.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CA.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.83NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.160.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
AY.4.2.4 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.161NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.58NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.75NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.411NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.217NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.35NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.17 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
B.1.1.41NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.527NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.500NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.147NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.487NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.68NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
B.1.1.121NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AA.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AS.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.115NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.127.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.88NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.168NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.36.39NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.57NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AH.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.289NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.365NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.252NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used